Table 1 Characteristics of the included clinical trials in the study
Study | Study design | Telbivudine/Control (n) | HBeAg (+) (-) (n) | Baseline ALT (U/L) | HBV DNA level(log copies/ml) | Treatment | Newborn immunization | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Telbivudine | Control | Telbivudine | Control | Telbivudine | Control | Lower enrollment limit | Telbivudine (mg/d) | Control | HBIG (IU) | HVB ac (mg) | |
Zhang 2009 [19] | RCT | 31/30 | NA | NA | NA | NA | Mean (SD): 7.38 (0.81) | Mean (SD): 7,460 (0.45 | 7 | 600 from 28-32 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
Zhao 2010 [22] | RCT | 30/30 | 30/0 | 30/0 | Normal (NA) | Normal (NA) | Positive (NA) | Positive (NA) | Positive (NA) | 600 from 28 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
Zeng 2010 [20] | NRCT | 22/26 | 22/0 | 26/0 | Normal NA) | Normal (NA) | Mean (SD): 7.66 (0.82) | Mean (SD): 7.13 (1.29) | 5 | 600 from 28 wk of gestation to delivery | No treatment | 200 at birth | 10 at 0, 1, 6 mo |
Zhang 2010 [21] | NRCY | 60/60 | 60/0 | 60/0 | NA | NA | Mean (SD): 7.66 (0.82) | Mean (SD): 6.86 (6,10) | 6 | 600 from 28 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
Yao 2011 [23] | NRCT | 28/30 | NA | NA | Mean (SD): 93.6 (226.8) | Mean (SD): 50.5 (5.5) | Mean (SD): 7.50 (0.60) | Mean (SD): 7.50 (0.70) | 6 | 600 fro 28 wk of getation to wk after delivery | No treatment | 200 at birth | 10 at 0, 1, 6H |
Han 2011 [5] | NRCT | 135/94 | 135/0 | 94/0 | Mean (SD): 35.67 (43.41 | Mean (SD): 42.53 (40.13) | Mean (SD): 8.10 (0.56) | Mean (SD): 7.98 (0.61) | 7 | 600 from 20-32 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 15 d | 20 at 0, 1, 6, |